全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

A Retrospective Study on Hepatitis C Virus Infected Individuals Lost to Follow-Up in Ticino: The Hub and Spoke Approach

DOI: 10.4236/ojim.2022.124021, PP. 194-198

Keywords: Hepatitis C, Follow-Up, Hepatocellular Carcinoma, Elimination of HCV, Epatocentro Ticino

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Approximately 71.1 million individuals are chronically infected with hepatitis C virus (HCV). The global incidence of HCV was 23.7 cases per 100,000 population in 2015, with an estimated 1.75 million new HCV infections diagnosed in 2015. In Switzerland, it is estimated that 37,000 patients have chronic HCV infection. In the Southern part of Switzerland liver disease patients are mainly followed at the six outpatient clinics of Epatocentro Ticino (EPT) connected with its hub in Lugano. The aim of the study was to identify lost to follow-up patients and reconnect them to specialist care. Methods: We used the database from EPT to identify HCV positive patients, who were lost to follow-up in the years 2007-2017. We consider lost to follow-up patients who had their last visit more than 2 years before closing date of analysis. We contacted the patients on the phone or by mail. Results: Overall 1271 patients have been at EPT between 2007 and 2017; of those 74 were lost to follow-up at the time of our screening. We received an answer from 60 of them. The results we collected were that 12 (6%) have died, 31 (42%) were currently followed by the General Practitioner (GP) or a different specialist, 9 (12%) were cured from HCV infection and did not need any further visit, and 4 (5%) refused to come for a check-up visit. In total, we rescued 4 (5%) patients and follow them at the EPT. Conclusion: Our look-back study revealed that our “Hub and Spoke-approach” had a high retention rate such that only 6% of our HCV patients were lost to follow-up. The look-back effort was still useful: the number of patients to recall identifying one patient needing treatment was 19.

References

[1]  WHO (2022) Hepatitis C.
https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
[2]  Blach, S., Schaetti, C., Bruggmann, P., Negro, F. and Razavi, H. (2019) Cost-Effectiveness Analysis of Strategies to Manage the Disease Burden of Hepatitis C Virus in Switzerland. Swiss Medical Weekly, 149, w20026.
https://doi.org/10.4414/smw.2019.20026
[3]  Rusch, U., Robbins, S., Razavi, H., et al. (2019) Microelimination of Chronic Hepatitis C in Switzerland: Modelling the Swiss Hepatitis Strategy Goals in Eastern, Western and Northern Regions. Swiss Medical Weekly, 149, w14694.
https://doi.org/10.4414/smw.2019.14694
[4]  Müllhaupt, B., Bruggmann, P., Bihl, F., et al. (2015) Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLOS ONE, 10, e0125214.
https://doi.org/10.1371/journal.pone.0125214
[5]  WHO (2022) Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis.
https://www.who.int/publications/i/item/WHO-HIV-2016.06
[6]  WHO (2017) Global Hepatitis Report, 2017.
https://www.who.int/publications/i/item/9789241565455
[7]  Coalition for Global Hepatitis Elimination (2022) Swiss Hepatitis Strategy 2014-2030.
https://www.globalhep.org/evidence-base/swiss-hepatitis-strategy-2014-2030
[8]  Bobzin, C., et al. (2021) Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. Swiss Medical Forum, 21, 184-186.
https://medicalforum.ch/de/detail/doi/smf.2021.08756
[9]  Arzneimittel Report.
https://www.helsana.ch/de/helsana-gruppe/medien-publikationen/helsanareports/arzneimittelreport.html

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133